Clinical Trial Update: Registry For Temsirolimus, Sunitinib, And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC), Mantle Cell Lymphoma (MCL), And Gastro-Intestinal Stroma Tumor (GIST) [STAR-TOR]

View source ↗

Summary

Pfizer-sponsored STAR-TOR registry study update reports completion and posted results for a three-drug regimen of temsirolimus, sunitinib, and axitinib in patie…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumor
• Mantle Cell Lymphoma
• Renal Cell Carcinoma

Drugs mentioned

• Inlyta (Axitinib) (Axitinib)
• Sutent (sunitinib) (sunitinib)
• Torisel (temsirolimus) (temsirolimus)

Snippet

Sponsor: Pfizer | Conditions: Carcinoma, Renal Cell, Advanced, Lymphoma, Mantle-Cell | Status: COMPLETED | Results posted: 2024-09-23